This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Multi-drug Resistant Tuberculosis
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to provide safety and efficacy data for TMC207 and to demonstrate that TMC207 added to a background regimen (BR) is superior to treatment with the BR plus placebo.

Provided treatments

  • Drug: Arm A Double-blind Phase: TMC207
  • Drug: Arm B Double-blind Phase: Placebo
  • Drug: Treatment Failure During Double-blind Phase: TMC207
  • Drug: Treatment Failure During Follow-up Phase: TMC207
Tris trial is registered with FDA with number: NCT01600963. The sponsor of the trial is Janssen Infectious Diseases BVBA and it is looking for 0 volunteers for the current phase.
Official trial title:
A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)